Circulating Tumor DNA Emerges as Powerful Prognostic Tool for Triple-Negative Breast Cancer Recurrence Risk
核心洞察
A tumor-informed ctDNA assay identified triple-negative breast cancer (搜索) patients with a nearly 30-fold higher risk of distant recurrence following neoadjuvant therapy and surgery.
Among patients with treatment-resistant tumors, those who were ctDNA-negative post-treatment achieved significantly better 3-year survival outcomes comparable to complete responders.
The findings from two major clinical trials suggest ctDNA testing could guide treatment decisions for both escalation in high-risk patients and de-escalation in low-risk cases.
Circulating tumor DNA (ctDNA) testing has demonstrated remarkable prognostic power in identifying triple-negative breast cancer (搜索) (TNBC (搜索)) patients at highest risk for distant recurrence, with new data showing a nearly 30-fold difference in recurrence risk based on minimal residual disease (MRD) status. The findings, presented from two major clinical trials, suggest liquid biopsy could transform treatment decision-making in early-stage breast cancer (搜索).
Dramatic Risk Stratification in Triple-Negative Disease
Results from a prespecified substudy of the phase 3 NSABP B-59/GBG 96-GeparDouze trial revealed that patients who were MRD-positive following neoadjuvant therapy and surgery had a 78% recurrence rate compared to just 5% in MRD-negative patients. The hazard ratio of 30.3 (95% CI, 10.4-88.7; P < .0001) represents one of the strongest prognostic signals reported in breast cancer (搜索).
"In patients who did not achieve pathological complete response (pCR), 21% of patients remained ctDNA positive, whereas in the pCR group, 2% of patients remained ctDNA positive," said lead author Marija Balic, MD, PhD, a hematologic oncologist at the UPMC Hillman Cancer Center (搜索).
The substudy analyzed 212 patients from the larger trial of 1,550 TNBC (搜索) patients who received neoadjuvant atezolizumab or placebo plus paclitaxel and carboplatin. At baseline, 96% of patients were ctDNA-positive, dropping to 9% after neoadjuvant treatment completion and just 6% after surgery.
Refining Risk in Treatment-Resistant Disease
Complementary data from the I-SPY2 trial, published in Nature Communications, demonstrated that ctDNA testing can refine risk stratification for patients with significant residual cancer burden (RCB) following neoadjuvant therapy. Among 723 patients with high-risk early-stage breast cancer (搜索), those with treatment-resistant tumors who remained ctDNA-negative achieved survival outcomes comparable to complete responders.
For patients with moderate residual disease (RCB-II), ctDNA-negative status was associated with 88% three-year distant recurrence-free survival compared to 57% for ctDNA-positive patients (adjusted HR, 0.29; P =.001). The difference was even more pronounced in extensive residual disease (RCB-III), with 83% versus 22% survival rates (adjusted HR, 0.14; P <.001).
"Refining risk stratification for NAT-resistant tumors using ctDNA and understanding ctDNA shedding in these tumors could guide treatment decisions to prevent or delay metastatic recurrence," wrote lead author Mark Jesus M. Magbanua, PhD, of the University of California, San Francisco.
Early Prediction Capabilities
Both studies highlighted ctDNA's potential for early response prediction. In the I-SPY2 analysis, patients who cleared ctDNA early—by week 3 or week 12 of treatment—had significantly higher three-year survival rates of 91% and 92%, respectively, compared to 35% for those with no clearance.
Early ctDNA clearance at week 3 was significantly associated with achieving favorable response across all receptor subtypes, including patients treated with targeted therapies and immunotherapies. This predictive capability held true for HER2-positive patients receiving trastuzumab and pertuzumab, as well as those with hormone receptor-positive and triple-negative disease treated with immune checkpoint inhibitors.
Technical Innovation and Biological Insights
The NSABP B-59 substudy employed a sophisticated tumor-informed approach, using whole exome sequencing to identify up to 200 somatic variants per patient (median 164.5 variants). Patient-specific probe sets were then used to detect these variants in plasma samples, with successful sequencing achieved in 98.4% of samples.
Notably, the I-SPY2 investigators found that less than 20% of patients with treatment-resistant tumors were ctDNA-positive post-treatment, despite high tumor burden. Serial mutation profiling revealed that patient-specific variants were conserved in residual tumor tissue in 94% of paired samples, suggesting that absent ctDNA detection reflects low shedding rather than assay limitations.
"This suggests that the absence of detectable ctDNA in resistant tumors is likely due to low shedding, which may characterize a biological phenotype with lower metastatic potential," the researchers noted.
Clinical Implementation Implications
The findings support integrating liquid biopsy into neoadjuvant treatment paradigms to guide both treatment escalation and de-escalation decisions. For patients with significant residual disease who are ctDNA-positive, the high recurrence risk warrants consideration for treatment intensification. Conversely, ctDNA-negative patients with resistant tumors may be candidates for de-escalation strategies to reduce unnecessary toxicity.
"This substudy is one of the largest evaluations of a bespoke MRD assay in prospectively collected serial blood samples from patients with TNBC (搜索)," Balic noted. "MRD-positive status was associated with a 30-fold higher risk of distant recurrence compared to patients who were MRD-negative and 95% of patients who were MRD-negative post-surgery remained free of disease at 3 years."
The convergent findings from both trials suggest ctDNA testing could become a standard component of breast cancer (搜索) care, offering unprecedented precision in identifying patients who would benefit most from aggressive treatment while sparing others from unnecessary interventions.